Nothing Special   »   [go: up one dir, main page]

MX366405B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX366405B
MX366405B MX2014014946A MX2014014946A MX366405B MX 366405 B MX366405 B MX 366405B MX 2014014946 A MX2014014946 A MX 2014014946A MX 2014014946 A MX2014014946 A MX 2014014946A MX 366405 B MX366405 B MX 366405B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2014014946A
Other languages
English (en)
Other versions
MX2014014946A (es
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014014946A publication Critical patent/MX2014014946A/es
Publication of MX366405B publication Critical patent/MX366405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a uso de péptidos GLP-1 de acción prolongada en ciertos regímenes de dosificación para el tratamiento de diabetes tipo 2, obesidad, etc.
MX2014014946A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX366405B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2014014946A MX2014014946A (es) 2015-04-08
MX366405B true MX366405B (es) 2019-07-08

Family

ID=49881374

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (11)

Country Link
US (2) US9764003B2 (es)
EP (3) EP4406593A3 (es)
JP (1) JP6059802B2 (es)
AU (3) AU2013286177B2 (es)
BR (1) BR112014032938A2 (es)
CA (1) CA2877056A1 (es)
MX (2) MX366405B (es)
RS (1) RS60432B1 (es)
RU (1) RU2657573C2 (es)
SI (1) SI2866825T1 (es)
WO (1) WO2014005858A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
MX366405B (es) 2012-07-01 2019-07-08 Novo Nordisk As Uso de peptidos glp-1 de accion prolongada.
CN110254223B (zh) * 2014-10-16 2022-03-25 洋马动力科技有限公司 拖拉机
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
MX2020003049A (es) * 2017-10-12 2020-07-27 Novo Nordisk As Semaglutida en la terapia medica.
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
PE20210453A1 (es) 2018-02-02 2021-03-08 Novo Nordisk As Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
US11492727B2 (en) * 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
AU2020377469A1 (en) * 2019-11-06 2022-04-28 Novo Nordisk A/S GLP-1 receptor agonists in dementia
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
US20240285729A1 (en) * 2021-06-24 2024-08-29 Gila Therapeutics, Inc. Methods and kits for inducing satiety and treating metabolic disorders
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN114874314B (zh) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 一种高表达glp-1类似物的重组工程菌及其构建方法
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
SI2932981T1 (sl) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
AU2005303777B2 (en) * 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX2008013216A (es) * 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
MX2011008416A (es) * 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
DK2513140T3 (en) 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
MX366405B (es) 2012-07-01 2019-07-08 Novo Nordisk As Uso de peptidos glp-1 de accion prolongada.

Also Published As

Publication number Publication date
MX2020010693A (es) 2020-11-06
RU2657573C2 (ru) 2018-06-14
SI2866825T1 (sl) 2020-07-31
EP4406593A3 (en) 2024-10-23
JP6059802B2 (ja) 2017-01-11
US20150190474A1 (en) 2015-07-09
JP2015522573A (ja) 2015-08-06
AU2013286177B2 (en) 2018-04-26
RS60432B1 (sr) 2020-07-31
EP2866825B1 (en) 2020-04-08
EP2866825A1 (en) 2015-05-06
AU2018202504A1 (en) 2018-05-10
AU2020202573A1 (en) 2020-05-07
CA2877056A1 (en) 2014-01-09
BR112014032938A2 (pt) 2017-08-01
US9764003B2 (en) 2017-09-19
US20180085435A1 (en) 2018-03-29
AU2020202573B2 (en) 2023-04-20
MX2014014946A (es) 2015-04-08
AU2018202504B2 (en) 2020-05-07
AU2013286177A1 (en) 2015-01-15
US10335462B2 (en) 2019-07-02
WO2014005858A1 (en) 2014-01-09
EP4406593A2 (en) 2024-07-31
EP3689365A1 (en) 2020-08-05
RU2015101826A (ru) 2016-08-20

Similar Documents

Publication Publication Date Title
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2014015423A (es) Analogos de peptido de exedina-4.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
IN2014CN02616A (es)
MX2015008114A (es) Derivados de exendina-4.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX347703B (es) Co-agonistas del receptor de glucagon/glp-1.
PH12015500115A1 (en) Glucagon analogues
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
PH12017500923A1 (en) New dosage and use of a a2a antagonist
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
NZ703573A (en) Feijoa fruit extract
AU2012240388A8 (en) Treatment regimens
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
TN2013000524A1 (en) Glucagon/glp-1 receptor co-agonists

Legal Events

Date Code Title Description
FG Grant or registration